Publications

Jobanputra V, Wrzeszczynski KO, Buttner R, Caldas C, Cuppen E, Grimmond S, Haferlach T, Mullighan C, Schuh A, Elemento O.  2021.  Clinical interpretation of whole-genome and whole-transcriptome sequencing for precision oncology.. Semin Cancer Biol.

Rosenquist R, Cuppen E, Buettner R, Caldas C, Dreau H, Elemento O, Frederix G, Grimmond S, Haferlach T, Jobanputra V et al..  2021.  Clinical utility of whole-genome sequencing in precision oncology.. Semin Cancer Biol.

Rosenquist R, Cuppen E, Buettner R, Caldas C, Dreau H, Elemento O, Frederix G, Grimmond S, Haferlach T, Jobanputra V et al..  2021.  Clinical utility of whole-genome sequencing in precision oncology.. Semin Cancer Biol.

Khosravi P, Lysandrou M, Eljalby M, Li Q, Kazemi E, Zisimopoulos P, Sigaras A, Brendel M, Barnes J, Ricketts C et al..  2021.  A Deep Learning Approach to Diagnostic Classification of Prostate Cancer Using Pathology-Radiology Fusion.. J Magn Reson Imaging. 54(2):462-471.

Cox N, Crozet L, Holtman IR, Loyher P-L, Lazarov T, White JB, Mass E, E Stanley R, Elemento O, Glass CK et al..  2021.  Diet-regulated production of PDGFcc by macrophages controls energy storage.. Science. 373(6550)

Cox N, Crozet L, Holtman IR, Loyher P-L, Lazarov T, White JB, Mass E, E Stanley R, Elemento O, Glass CK et al..  2021.  Diet-regulated production of PDGFcc by macrophages controls energy storage.. Science. 373(6550)

Pan H, Renaud L, Chaligne R, Bloehdorn J, Tausch E, Mertens D, Fink AMaria, Fischer K, Zhang C, Betel D et al..  2021.  Discovery of candidate DNA methylation cancer driver genes.. Cancer Discov.

Montrose DC, Saha S, Foronda M, McNally EM, Chen J, Zhou XKathy, Ha T, Krumsiek J, Buyukozkan M, Verma A et al..  2021.  Exogenous and Endogenous Sources of Serine Contribute to Colon Cancer Metabolism, Growth, and Resistance to 5-Fluorouracil.. Cancer Res. 81(9):2275-2288.

Montrose DC, Saha S, Foronda M, McNally EM, Chen J, Zhou XKathy, Ha T, Krumsiek J, Buyukozkan M, Verma A et al..  2021.  Exogenous and Endogenous Sources of Serine Contribute to Colon Cancer Metabolism, Growth, and Resistance to 5-Fluorouracil.. Cancer Res. 81(9):2275-2288.

Yusufova N, Kloetgen A, Teater M, Osunsade A, Camarillo JM, Chin CR, Doane AS, Venters BJ, Portillo-Ledesma S, Conway J et al..  2021.  Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture.. Nature. 589(7841):299-305.

Yusufova N, Kloetgen A, Teater M, Osunsade A, Camarillo JM, Chin CR, Doane AS, Venters BJ, Portillo-Ledesma S, Conway J et al..  2021.  Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture.. Nature. 589(7841):299-305.

Yusufova N, Kloetgen A, Teater M, Osunsade A, Camarillo JM, Chin CR, Doane AS, Venters BJ, Portillo-Ledesma S, Conway J et al..  2021.  Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture.. Nature. 589(7841):299-305.

Yusufova N, Kloetgen A, Teater M, Osunsade A, Camarillo JM, Chin CR, Doane AS, Venters BJ, Portillo-Ledesma S, Conway J et al..  2021.  Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture.. Nature. 589(7841):299-305.

Marderstein AR, Davenport ER, Kulm S, Van Hout CV, Elemento O, Clark AG.  2021.  Leveraging phenotypic variability to identify genetic interactions in human phenotypes.. Am J Hum Genet. 108(1):49-67.

Kaya C, Dorsaint P, Mercurio S, Campbell AM, Eng KWha, Nikiforova MN, Elemento O, Nikiforov YE, Sboner A.  2021.  Limitations of Detecting Genetic Variants from the RNA Sequencing Data in Tissue and Fine-Needle Aspiration Samples.. Thyroid. 31(4):589-595.

Nie K, Redmond D, Eng KW, Zhang T, Cheng S, Mathew S, Elemento O, Tam W.  2021.  Mutation landscape, clonal evolution pattern, and potential pathogenic pathways in B-lymphoblastic transformation of follicular lymphoma.. Leukemia. 35(4):1203-1208.

Altorki NK, McGraw TE, Borczuk AC, Saxena A, Port JL, Stiles BM, Lee BE, Sanfilippo NJ, Scheff RJ, Pua BB et al..  2021.  Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.. Lancet Oncol. 22(6):824-835.

Rendeiro AF, Casano J, Vorkas CKyriakos, Singh H, Morales A, DeSimone RA, Ellsworth GB, Soave R, Kapadia SN, Saito K et al..  2021.  Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression.. Life Sci Alliance. 4(2)

Rendeiro AF, Casano J, Vorkas CKyriakos, Singh H, Morales A, DeSimone RA, Ellsworth GB, Soave R, Kapadia SN, Saito K et al..  2021.  Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression.. Life Sci Alliance. 4(2)

Rendeiro AF, Casano J, Vorkas CKyriakos, Singh H, Morales A, DeSimone RA, Ellsworth GB, Soave R, Kapadia SN, Saito K et al..  2021.  Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression.. Life Sci Alliance. 4(2)

Rendeiro AF, Casano J, Vorkas CKyriakos, Singh H, Morales A, DeSimone RA, Ellsworth GB, Soave R, Kapadia SN, Saito K et al..  2021.  Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression.. Life Sci Alliance. 4(2)

Dixon G, Pan H, Yang D, Rosen BP, Jashari T, Verma N, Pulecio J, Caspi I, Lee K, Stransky S et al..  2021.  QSER1 protects DNA methylation valleys from de novo methylation.. Science. 372(6538)

Rivas MA, Meydan C, Chin CR, Challman MF, Kim D, Bhinder B, Kloetgen A, Viny AD, Teater MR, McNally DR et al..  2021.  Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation.. Nat Immunol. 22(2):240-253.

Rivas MA, Meydan C, Chin CR, Challman MF, Kim D, Bhinder B, Kloetgen A, Viny AD, Teater MR, McNally DR et al..  2021.  Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation.. Nat Immunol. 22(2):240-253.

Rivas MA, Meydan C, Chin CR, Challman MF, Kim D, Bhinder B, Kloetgen A, Viny AD, Teater MR, McNally DR et al..  2021.  Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation.. Nat Immunol. 22(2):240-253.